nodes	percent_of_prediction	percent_of_DWPC	metapath
Fesoterodine—CHRM4—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0223	0.0269	CbGpPWpGaD
Fesoterodine—CHRM5—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0213	0.0258	CbGpPWpGaD
Fesoterodine—CHRM4—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.019	0.023	CbGpPWpGaD
Fesoterodine—CHRM4—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0184	0.0223	CbGpPWpGaD
Fesoterodine—CHRM5—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0182	0.022	CbGpPWpGaD
Fesoterodine—CHRM5—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0177	0.0214	CbGpPWpGaD
Fesoterodine—CHRM4—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0172	0.0208	CbGpPWpGaD
Fesoterodine—CHRM5—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0164	0.0199	CbGpPWpGaD
Fesoterodine—CHRM4—nervous system—Gilles de la Tourette syndrome	0.0163	0.0941	CbGeAlD
Fesoterodine—CHRM4—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.016	0.0193	CbGpPWpGaD
Fesoterodine—CHRM4—central nervous system—Gilles de la Tourette syndrome	0.0157	0.0906	CbGeAlD
Fesoterodine—CHRM4—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0155	0.0187	CbGpPWpGaD
Fesoterodine—CHRM5—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0153	0.0185	CbGpPWpGaD
Fesoterodine—CHRM1—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.015	0.0182	CbGpPWpGaD
Fesoterodine—CHRM3—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.015	0.0181	CbGpPWpGaD
Fesoterodine—CHRM5—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0148	0.018	CbGpPWpGaD
Fesoterodine—CHRM2—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0148	0.0179	CbGpPWpGaD
Fesoterodine—CHRM4—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0144	0.0175	CbGpPWpGaD
Fesoterodine—CHRM5—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0138	0.0167	CbGpPWpGaD
Fesoterodine—CHRM1—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0128	0.0155	CbGpPWpGaD
Fesoterodine—CHRM3—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0128	0.0154	CbGpPWpGaD
Fesoterodine—CHRM5—nervous system—Gilles de la Tourette syndrome	0.0128	0.0735	CbGeAlD
Fesoterodine—CHRM2—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0126	0.0153	CbGpPWpGaD
Fesoterodine—CHRM4—brain—Gilles de la Tourette syndrome	0.0125	0.0719	CbGeAlD
Fesoterodine—CHRM1—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0124	0.015	CbGpPWpGaD
Fesoterodine—CHRM3—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0124	0.015	CbGpPWpGaD
Fesoterodine—CHRM5—central nervous system—Gilles de la Tourette syndrome	0.0123	0.0708	CbGeAlD
Fesoterodine—CHRM2—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0123	0.0148	CbGpPWpGaD
Fesoterodine—CHRM4—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.012	0.0146	CbGpPWpGaD
Fesoterodine—CHRM1—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0116	0.014	CbGpPWpGaD
Fesoterodine—CHRM3—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0115	0.014	CbGpPWpGaD
Fesoterodine—CHRM5—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0115	0.0139	CbGpPWpGaD
Fesoterodine—CHRM2—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0114	0.0138	CbGpPWpGaD
Fesoterodine—CHRM1—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0108	0.013	CbGpPWpGaD
Fesoterodine—CHRM3—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0107	0.013	CbGpPWpGaD
Fesoterodine—CHRM2—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0106	0.0129	CbGpPWpGaD
Fesoterodine—CHRM1—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0104	0.0126	CbGpPWpGaD
Fesoterodine—CHRM3—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0104	0.0126	CbGpPWpGaD
Fesoterodine—CHRM2—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0103	0.0125	CbGpPWpGaD
Fesoterodine—CHRM4—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.0101	0.0122	CbGpPWpGaD
Fesoterodine—CHRM5—brain—Gilles de la Tourette syndrome	0.00975	0.0562	CbGeAlD
Fesoterodine—CHRM1—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.00973	0.0118	CbGpPWpGaD
Fesoterodine—CHRM3—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0097	0.0117	CbGpPWpGaD
Fesoterodine—CHRM5—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00968	0.0117	CbGpPWpGaD
Fesoterodine—CHRM2—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.00961	0.0116	CbGpPWpGaD
Fesoterodine—CHRM2—nervous system—Gilles de la Tourette syndrome	0.00876	0.0505	CbGeAlD
Fesoterodine—CHRM2—central nervous system—Gilles de la Tourette syndrome	0.00843	0.0486	CbGeAlD
Fesoterodine—CHRM1—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00811	0.00981	CbGpPWpGaD
Fesoterodine—CHRM3—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00808	0.00978	CbGpPWpGaD
Fesoterodine—CHRM2—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00801	0.00969	CbGpPWpGaD
Fesoterodine—CHRM1—nervous system—Gilles de la Tourette syndrome	0.00797	0.0459	CbGeAlD
Fesoterodine—CHRM1—central nervous system—Gilles de la Tourette syndrome	0.00767	0.0442	CbGeAlD
Fesoterodine—CHRM3—nervous system—Gilles de la Tourette syndrome	0.00713	0.0411	CbGeAlD
Fesoterodine—CHRM3—central nervous system—Gilles de la Tourette syndrome	0.00687	0.0396	CbGeAlD
Fesoterodine—CHRM1—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00682	0.00825	CbGpPWpGaD
Fesoterodine—CHRM3—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.0068	0.00822	CbGpPWpGaD
Fesoterodine—CHRM2—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00673	0.00814	CbGpPWpGaD
Fesoterodine—CHRM2—brain—Gilles de la Tourette syndrome	0.00669	0.0386	CbGeAlD
Fesoterodine—CHRM1—brain—Gilles de la Tourette syndrome	0.00609	0.0351	CbGeAlD
Fesoterodine—CHRM3—GPCRs, Other—DRD3—Gilles de la Tourette syndrome	0.00567	0.00686	CbGpPWpGaD
Fesoterodine—CHRM2—GPCRs, Other—DRD3—Gilles de la Tourette syndrome	0.00561	0.00679	CbGpPWpGaD
Fesoterodine—CHRM3—GPCRs, Other—DRD4—Gilles de la Tourette syndrome	0.0055	0.00666	CbGpPWpGaD
Fesoterodine—CHRM3—brain—Gilles de la Tourette syndrome	0.00545	0.0314	CbGeAlD
Fesoterodine—CHRM2—GPCRs, Other—DRD4—Gilles de la Tourette syndrome	0.00545	0.00659	CbGpPWpGaD
Fesoterodine—CHRM4—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00395	0.00478	CbGpPWpGaD
Fesoterodine—CYP3A4—nervous system—Gilles de la Tourette syndrome	0.00392	0.0226	CbGeAlD
Fesoterodine—CYP2D6—nervous system—Gilles de la Tourette syndrome	0.00386	0.0222	CbGeAlD
Fesoterodine—CHRM4—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00383	0.00464	CbGpPWpGaD
Fesoterodine—CYP3A4—central nervous system—Gilles de la Tourette syndrome	0.00377	0.0217	CbGeAlD
Fesoterodine—CYP2D6—central nervous system—Gilles de la Tourette syndrome	0.00371	0.0214	CbGeAlD
Fesoterodine—CHRM4—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00366	0.00443	CbGpPWpGaD
Fesoterodine—CHRM3—GPCRs, Other—HTR2A—Gilles de la Tourette syndrome	0.00359	0.00434	CbGpPWpGaD
Fesoterodine—CHRM4—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00357	0.00432	CbGpPWpGaD
Fesoterodine—CHRM4—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00356	0.0043	CbGpPWpGaD
Fesoterodine—CHRM2—GPCRs, Other—HTR2A—Gilles de la Tourette syndrome	0.00356	0.0043	CbGpPWpGaD
Fesoterodine—CHRM5—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00351	0.00425	CbGpPWpGaD
Fesoterodine—CHRM5—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00341	0.00412	CbGpPWpGaD
Fesoterodine—ABCB1—midbrain—Gilles de la Tourette syndrome	0.00337	0.0194	CbGeAlD
Fesoterodine—CHRM4—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00331	0.00401	CbGpPWpGaD
Fesoterodine—CHRM5—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00317	0.00384	CbGpPWpGaD
Fesoterodine—CHRM4—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00314	0.0038	CbGpPWpGaD
Fesoterodine—CHRM4—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00305	0.00369	CbGpPWpGaD
Fesoterodine—CHRM1—Circadian rythm related genes—DRD3—Gilles de la Tourette syndrome	0.00302	0.00365	CbGpPWpGaD
Fesoterodine—CHRM5—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00301	0.00364	CbGpPWpGaD
Fesoterodine—CYP2D6—brain—Gilles de la Tourette syndrome	0.00295	0.017	CbGeAlD
Fesoterodine—CHRM1—Circadian rythm related genes—DRD4—Gilles de la Tourette syndrome	0.00293	0.00354	CbGpPWpGaD
Fesoterodine—CHRM5—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00292	0.00353	CbGpPWpGaD
Fesoterodine—CHRM5—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.00288	0.00348	CbGpPWpGaD
Fesoterodine—CHRM4—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00284	0.00344	CbGpPWpGaD
Fesoterodine—ABCB1—nervous system—Gilles de la Tourette syndrome	0.00277	0.016	CbGeAlD
Fesoterodine—CHRM1—Circadian rythm related genes—DRD2—Gilles de la Tourette syndrome	0.00273	0.0033	CbGpPWpGaD
Fesoterodine—CHRM5—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00272	0.00329	CbGpPWpGaD
Fesoterodine—ABCB1—central nervous system—Gilles de la Tourette syndrome	0.00267	0.0154	CbGeAlD
Fesoterodine—CHRM2—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00263	0.00318	CbGpPWpGaD
Fesoterodine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00257	0.00311	CbGpPWpGaD
Fesoterodine—CHRM2—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00255	0.00309	CbGpPWpGaD
Fesoterodine—CHRM1—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00247	0.00299	CbGpPWpGaD
Fesoterodine—CHRM3—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00246	0.00298	CbGpPWpGaD
Fesoterodine—CHRM2—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00244	0.00295	CbGpPWpGaD
Fesoterodine—CHRM1—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.0024	0.0029	CbGpPWpGaD
Fesoterodine—CHRM3—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00239	0.00289	CbGpPWpGaD
Fesoterodine—CHRM4—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00239	0.00289	CbGpPWpGaD
Fesoterodine—CHRM2—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00238	0.00288	CbGpPWpGaD
Fesoterodine—CHRM2—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00237	0.00287	CbGpPWpGaD
Fesoterodine—CHRM4—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00232	0.00281	CbGpPWpGaD
Fesoterodine—CHRM4—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00232	0.00281	CbGpPWpGaD
Fesoterodine—CHRM2—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.00231	0.0028	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00229	0.00277	CbGpPWpGaD
Fesoterodine—CHRM1—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00223	0.0027	CbGpPWpGaD
Fesoterodine—CHRM3—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00223	0.0027	CbGpPWpGaD
Fesoterodine—CHRM5—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00222	0.00269	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00222	0.00269	CbGpPWpGaD
Fesoterodine—CHRM2—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00221	0.00267	CbGpPWpGaD
Fesoterodine—CHRM4—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00216	0.00262	CbGpPWpGaD
Fesoterodine—ABCB1—brain—Gilles de la Tourette syndrome	0.00212	0.0122	CbGeAlD
Fesoterodine—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00212	0.00256	CbGpPWpGaD
Fesoterodine—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00211	0.00255	CbGpPWpGaD
Fesoterodine—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00209	0.00253	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00207	0.00251	CbGpPWpGaD
Fesoterodine—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00206	0.00249	CbGpPWpGaD
Fesoterodine—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00205	0.00248	CbGpPWpGaD
Fesoterodine—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00203	0.00245	CbGpPWpGaD
Fesoterodine—CHRM1—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.00202	0.00245	CbGpPWpGaD
Fesoterodine—CHRM3—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.00202	0.00244	CbGpPWpGaD
Fesoterodine—CHRM4—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00199	0.00241	CbGpPWpGaD
Fesoterodine—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00191	0.00232	CbGpPWpGaD
Fesoterodine—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00191	0.00231	CbGpPWpGaD
Fesoterodine—CHRM5—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.0019	0.0023	CbGpPWpGaD
Fesoterodine—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00189	0.00229	CbGpPWpGaD
Fesoterodine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00181	0.00219	CbGpPWpGaD
Fesoterodine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00181	0.00218	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00161	0.00195	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00161	0.00194	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00159	0.00193	CbGpPWpGaD
Fesoterodine—CHRM1—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00157	0.00189	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00157	0.00189	CbGpPWpGaD
Fesoterodine—CHRM3—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00156	0.00189	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00156	0.00189	CbGpPWpGaD
Fesoterodine—CHRM2—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00154	0.00187	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00154	0.00187	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—HDC—Gilles de la Tourette syndrome	0.00154	0.00186	CbGpPWpGaD
Fesoterodine—CHRM4—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00151	0.00183	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00146	0.00176	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00145	0.00176	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00145	0.00175	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00144	0.00174	CbGpPWpGaD
Fesoterodine—CHRM4—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00135	0.00163	CbGpPWpGaD
Fesoterodine—CHRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00134	0.00162	CbGpPWpGaD
Fesoterodine—CHRM3—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00134	0.00162	CbGpPWpGaD
Fesoterodine—CHRM2—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00132	0.0016	CbGpPWpGaD
Fesoterodine—CHRM4—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00131	0.00159	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00129	0.00157	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00126	0.00152	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00123	0.00148	CbGpPWpGaD
Fesoterodine—CHRM4—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00122	0.00148	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00119	0.00144	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00118	0.00142	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00117	0.00142	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00114	0.00138	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00111	0.00134	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00106	0.00129	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00102	0.00124	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00102	0.00123	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00101	0.00122	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—HDC—Gilles de la Tourette syndrome	0.000978	0.00118	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—HDC—Gilles de la Tourette syndrome	0.000921	0.00111	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000911	0.0011	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000908	0.0011	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000899	0.00109	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000884	0.00107	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000882	0.00107	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000873	0.00106	CbGpPWpGaD
Fesoterodine—CHRM4—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000856	0.00104	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000827	0.001	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000825	0.000998	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000824	0.000997	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000821	0.000994	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.00082	0.000992	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000817	0.000988	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000813	0.000984	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000803	0.000972	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000801	0.000969	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000793	0.000959	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000777	0.00094	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000748	0.000905	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000746	0.000902	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000744	0.0009	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000739	0.000894	CbGpPWpGaD
Fesoterodine—ABCB1—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.000726	0.000879	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000725	0.000877	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000704	0.000851	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000694	0.00084	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000674	0.000815	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000656	0.000793	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000628	0.00076	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—HDC—Gilles de la Tourette syndrome	0.000602	0.000729	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000577	0.000698	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000575	0.000696	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.00057	0.000689	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000524	0.000634	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000522	0.000632	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000517	0.000626	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000489	0.000591	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000487	0.000589	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000482	0.000584	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000474	0.000574	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000473	0.000572	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000468	0.000567	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000459	0.000555	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000442	0.000535	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000441	0.000533	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.00044	0.000532	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000436	0.000528	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.00031	0.000375	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000309	0.000373	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000306	0.00037	CbGpPWpGaD
